(UroToday.com) In a plenary session at the American Urologic Association (AUA) Virtual Annual Meeting this afternoon, Dr. Angela Smith moderated a session examining “Pain Management in Urologic Surgery”. Along with panelists Drs. Jay Simhan, Nicole Miller, and Ben Davies, Dr. Smith highlights issues relating to opioid use both widely in the community and specifically among surgical […]
(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), adjuvant treatment with BCG is guideline-recommended on the basis of proven benefits in disease recurrence. While BCG is efficacious, many patients eventually develop BCG-unresponsive disease.
(UroToday.com) PSA screening can reduce prostate cancer mortality. However, screening remains relatively underused in younger, healthy men, and overused in the older less healthy population. A retrospective cross-sectional study among men aged 50 years or older showed that between 2015 and 2018 there was no significant increase in the PSA-based prostate cancer screening. However, a significant […]
(UroToday.com) Despite advances in biomarker development, early detection of aggressive prostate cancer (Gleason Group 3-5) continues to pose significant clinical challenges. Several authors involved in this study previously developed the Michigan Prostate Score for individualized risk prediction of aggressive prostate cancer.1 The Michigan Prostate Score uses transcription-mediated amplification to quantify expression of TMPRSS2:ERG and PCA3 from […]
(UroToday.com) Radical cystectomy (RC) is known to have significant perioperative complications with rates of readmission approaching 50% in some series. The use of robotic approaches was hoped to decrease the morbidity associated with radical cystectomy. This is supported by retrospective cohort studies. While powered for oncologic outcomes, the RAZOR trial is the largest randomized trial that […]
(UroToday.com) The AUA 2020 virtual meeting State of the Art Lecture was provided by Dr. Jeremy Burton, discussing probiotics and microbiota in urology. Dr. Burton started by highlighting that the microbiome impacts urological conditions and that we need new ways of delivery, new bacterial types, and more applications. However, to embark on new probiotic and microbial […]
(UroToday.com) In the initial publication of the PURE-01 study, Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma (PURE-01), neoadjuvant immunotherapy with three cycles of pembrolizumab was associated with a complete response (pT0N0) of 42% and a partial (pT1N0 or less) of 54%.1 While biomarkers associated with pathologic response included higher tumor mutational burden and alterations in DNA […]
(UroToday.com) Laurence Klotz, MD, FRCSC, gave a presentation elaborating on how to reduce the morbidity and improve the outcomes of androgen deprivation therapy (ADT) at the American Urological Association (AUA) 2020 Virtual Annual Meeting. The objectives of this talk were to understand the long-term effects of ADT and its association with cardiac disease, metabolic syndrome, […]
(UroToday.com) There has been increasing utilization of minimally invasive approaches for partial nephrectomy, in particular the use of robotic-assisted surgery. While there are expected benefits to this approach, there is no randomized data demonstrating benefit. In a podium presentation at the American Urologic Association (AUA) 2020 Virtual Annual Meeting, Alessandro Larcher, MD, and colleagues presented a […]
(UroToday.com) In patients with muscle-invasive bladder cancer, pre-operative staging is typically performed with computed tomography. Prior work has demonstrated that in patients without clinical evidence of nodal disease based on conventional imaging, the use of fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomography (CT) prior to neoadjuvant chemotherapy and radical cystectomy (RC) or RC alone has limited utility. In […]
